LinkedIn facebook twitter youtube
News archive


 Myeloma Patients Europe (MPE) is pleased to announce that Denis Henrard, an experienced manager in the healthcare sector, has been appointed Chief Executive Officer (CEO). This follows last year’s news that the founding CEO of MPE, Ananda Plate, stood down from the role after ten very successful years.


Denis started at MPE on 1 May 2022 and will be responsible for overall strategy and leadership at the organisation. He brings to the role a 20-year career in the health sector, where he held roles at diagnostic, medical device, and pharmaceutical companies, as well as with global consulting firms. He has significant expertise in leadership and team management and is committed to building on MPE’s achievements to date and ushering in the next era of the organisation.


Denis Henrard, CEO of MPE commented:


“I am delighted to join MPE and bring my expertise and knowledge to the myeloma patient community. MPE and its members have done wonderful work in the last decade, and I am pleased to collaborate with the MPE membership to improve myeloma and AL amyloidosis patients’ lives.”


Hans Scheurer, Interim CEO and former President of MPE commented:


“The MPE family welcomes Denis in his new role as CEO. His expertise and motivation will make it possible to continue the impressive work done by the founding CEO, Ananda Plate and the MPE staff. I will be stepping down as Interim CEO on 1 May and look forward to handing the baton to an experienced leader who will continue to help improve diagnosis, treatment and the quality of life of myeloma and AL amyloidosis patients across Europe.”


Over the coming weeks and months, Denis will be meeting with MPE members, sponsors and other partners to introduce himself, and discuss existing work with MPE and opportunities for the future. In the meantime, if you have any questions or comments about his appointment, please email info@mpeurope.org 

Recent news

» Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

» Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy